MENU
+Compare
IBB
ETF ticker: NASDAQ
AS OF
Feb 3, 04:59 PM (EDT)
Price
$173.83
Change
+$21.78 (+14.32%)
Net Assets
8.53B

IBB stock forecast, quote, news & analysis

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U... Show more

Category: #Health
IBB
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for IBB with price predictions
Feb 02, 2026

IBB in +0.90% Uptrend, rising for three consecutive days on January 27, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IBB advanced for three days, in of 331 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 13, 2026. You may want to consider a long position or call options on IBB as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where IBB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for IBB turned negative on January 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IBB broke above its upper Bollinger Band on January 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Market Cap

The average market capitalization across the iShares Biotechnology ETF ETF is 6.61B. The market cap for tickers in the group ranges from 14.86M to 185.6B. AMGN holds the highest valuation in this group at 185.6B. The lowest valued company is APLT at 14.86M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Biotechnology ETF ETF was 92%. For the same ETF, the average monthly price growth was 214%, and the average quarterly price growth was 625%. CATX experienced the highest price growth at 95%, while TKNO experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the iShares Biotechnology ETF ETF was 0%. For the same stocks of the ETF, the average monthly volume growth was 2% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 76
Price Growth Rating: 49
SMR Rating: 88
Profit Risk Rating: 87
Seasonality Score: -35 (-100 ... +100)
View a ticker or compare two or three
IBB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com